Search the Newsreel

Magnachip Semiconductor (NYSE: MX) director awarded 39,286 common shares

Magnachip Semiconductor director Camillo Martino was granted 39,286 shares of Common Stock on August 1, 2026, at a price of $0.00 per share. Following this transaction, Martino directly owns 403,897 shares and indirectly holds an additional 40,000 shares through a trust. This grant is …

Bank of America (NYSE: BAC) discloses 7.0% ownership stake in CytomX (CTMX)

Bank of America Corporation has filed a Schedule 13G, revealing a 7.0% beneficial ownership stake in CytomX Therapeutics, Inc. This stake, amounting to 15,134,689 shares, is primarily held through its wholly-owned subsidiaries, including BofA Securities, Inc. and Merrill Lynch entities. While Bank of America …

Methanex (TSX:MX) Boosts Material Stocks Following Quarterly Results

Form 4 MAGNACHIP SEMICONDUCTOR Corp For: 3 August By Investing.com

This article announces a Form 4 filing for MAGNACHIP SEMICONDUCTOR Corp on August 3rd, as reported by Investing.com. It is a brief, procedural notice indicating an insider transaction or change in ownership that companies are required to disclose to the SEC. The content is …

Magnachip Semiconductor (NYSE: MX) director receives 46,429-share grant

Magnachip Semiconductor director Cristiano Amoruso received a grant of 46,429 shares of Common Stock on August 1, 2026, at no cash cost. This transaction increased his direct holdings to 75,057 shares, in addition to 3,072,779 shares held indirectly through Byreforge LLC. The grant was …

Methanex (TSX:MX) Posts Stronger Earnings And Output, Is It Still Cheap?

InvestingPro’s Fair Value predicted 46% drop in CytomX stock By Investing.com

InvestingPro's Fair Value analysis accurately predicted a 46% drop in CytomX Therapeutics (NASDAQ:CTMX) stock. The analysis, conducted in January 2026 when the stock was trading at $5.73, identified significant overvaluation. Six months later, shares had fallen to $3.10, validating InvestingPro's methodology which aggregates various …

Royal Bank of Canada Sells 362,099 Shares of Methanex Corporation $MEOH

MX|MagnaChip Semiconductor Corp|Price:3.260|

This article provides a comprehensive stock analysis of MagnaChip Semiconductor Corp (MX) from TradingKey, highlighting its healthy fundamentals and significant growth potential, despite a recent weak stock market performance. It notes the company's valuation as fairly valued within its industry, high institutional ownership, and …

SMX (Security Matters) Public Limited Company Revenue Breakdown – NASDAQ:SMX

BlackRock, Inc. Adds to CytomX Therapeutics Inc (CTMX) Stake -- Shares Look 1007% Overvalued on GF Value

BlackRock, Inc. increased its stake in CytomX Therapeutics Inc (CTMX) by 216.58% on June 30, 2026, purchasing 11,323,172 additional shares at $3.75 each, despite the stock being deemed significantly overvalued by GuruFocus. As of August 1, 2026, CTMX shares had dropped to $3.10, resulting …

CytomX Therapeutics (CTMX) awards 118,000 stock options to board director

CytomX Therapeutics awarded 118,000 stock options to board director Charles S. Fuchs. The options have an exercise price of $3.24 per share, expire on July 23, 2036, and vest over three years starting from July 24, 2026, contingent on his continued service. This transaction …

Magnachip Semiconductor Q2 Earnings Call Highlights

Magnachip Semiconductor reported a Q2 revenue decline to $44.7 million, down 6.1% year-over-year, due to weaker demand and pricing pressure on legacy products, though gross margin improved sequentially to 19.3%. New CEO Chae Lee is refocusing the company on differentiated, application-specific power semiconductors and …

TMX Group Limited 2026 Q2 - Results - Earnings Call Presentation (TSX:X:CA) 2026-07-31

Form 4 CytomX Therapeutics Inc For: 31 July By Investing.com

This article reports on a Form 4 filing for CytomX Therapeutics Inc. dated July 31st. It indicates that the filing is available through Investing.com, a financial markets platform. The content is primarily a placeholder for the actual Form 4 document.

TMX Group Limited Increases Dividend by 8% to $0.26 per Common Share

Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - The Board of Directors of TMX Group Limited today declared a dividend of $0.26 on each common share outstanding, an increase of $0.02 or 8%. This dividend is payable on August 28, 2026 to shareholders of …

TMX Group Limited Reports Results for the Second Quarter of 2026

Revenue of $487.5 million, up 16% from $421.7 million in Q2/25 Diluted earnings per share of $0.51, up 96% from $0.26 in Q2/25, including a 20 cent per share increase related to net foreign exchange gains in Q2/26 compared with losses in Q2/25 Adjusted …

CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced it will report its second quarter 2026 financial results on Thursday, August 6, 2026, after the close of U.S. markets. The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT following …

CytomX's second-quarter results call is set for Aug. 6 at 5 p.m. ET

CytomX Therapeutics (Nasdaq: CTMX) is scheduled to report its second-quarter 2026 financial results on August 6, 2026, after market close, followed by a conference call and webcast at 5:00 p.m. ET. The company, which is a clinical-stage, oncology-focused biopharmaceutical firm developing PROBODY therapeutics, has …

CytomX Therapeutics (CTMX) Projected to Announce Quarterly Earnings on Thursday

Methanex (TSX:MX) Stock Profit Rebound Meets Leverage And Margin Doubts

Operating cash flow per share of CytomX Therapeutics, Inc. – LSX:A14158

This article provides financial information for CytomX Therapeutics, Inc. (LSX:A14158), specifically focusing on its operating cash flow per share. The content presents a table showing the value, change, and percentage change over a given period, stating that this information was "Made by humans."

Magnachip outlines Q3 revenue $41.5M-$45.5M while targeting 10% new-generation product revenue in Q4 2026

Earnings Call Insights: Magnachip Semiconductor (MX) Q2 2026 MANAGEMENT VIEW * Camillo Martino framed the CEO transition as central to the company’s repositioning, saying, “Over the past several months, we've taken important steps to reposition Magnachip as a pure-play power semiconductor company,” and adding, …

Earnings call transcript: Magnachip posts mixed Q2 2026 results, shares fall

Magnachip Semiconductor reported mixed second-quarter 2026 results, surpassing earnings expectations but falling short on revenue, leading to a significant drop in its shares. The company is actively transitioning to become a pure-play power semiconductor company, focusing on differentiated products and long-term value, and has …

Magnachip Q2 revenue falls 6 percent to $44.7 million

Magnachip Semiconductor (MX) reported a 6.1% decrease in Q2 2026 consolidated revenue, falling to $44.7 million. The company recorded a GAAP net loss of $4.8 million but achieved a gross profit margin of 19.3%, exceeding its guidance. Magnachip also named Chae Lee as CEO …

Methanex Q2 Earnings Call Highlights

Key Points Interested in Methanex Corporation? Here are five stocks we like better. Strong Q2 results: Methanex reported $577 million in adjusted EBITDA and $300 million in adjusted net income, supported by higher methanol prices and record North American production. The company repaid its …

Methanex's Q2 Earnings Miss Estimates Despite Strong Methanol Pricing

Methanex Corporation MEOH reported adjusted earnings of $3.87 per share for the second quarter of 2026, up sharply from 97 cents in the year-ago quarter. The figure missed the Zacks Consensus Estimate of $4.00. The year-over-year improvement reflected a significantly higher average realized methanol …

CytomX Therapeutics Inc (CTMX) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of CytomX Therapeutics Inc (CTMX), reporting its current financial score as 7.59, which ranks it 106 out of 385 in the Biotechnology & Medical Research industry. While its financial status is stable and operating efficiency is high, the …

Methanex Posts Record Q2 2026 Earnings and North American Output, Idles Trinidad Titan Plant

Methanex Corporation Q2 Income Advances

(RTTNews) - Methanex Corporation (MEOH) released a profit for its second quarter that Increases, from the same period last year The company's earnings came in at $197.83 million, or $2.45 per share. This compares with $64.41 million, or $0.93 per share, last year. Excluding …

Methanex (MEOH) Q2 Earnings and Revenues Lag Estimates

Methanex (MEOH) came out with quarterly earnings of $3.87 per share, missing the Zacks Consensus Estimate of $4 per share. This compares to earnings of $0.97 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

SMX Security Matters (Nasdaq: SMX) ups equity plan, grants RSUs

SMX Security Matters Public Limited Company (Nasdaq: SMX) has amended its 2022 Incentive Equity Plan, increasing the authorized Ordinary Shares from 671,641 to 781,641 without stockholder approval, leveraging its status as a Foreign Private Issuer. Following this, the company granted 100,000 restricted stock units …

Eversept Partners LP Has $14.99 Million Stock Holdings in CytomX Therapeutics, Inc. $CTMX

Methanex Reports Record North American Production and Second Quarter 2026 Earnings

Except where otherwise noted, all currency amounts are stated in United States dollars. Financial and Production Highlights Net income attributable to Methanex shareholders of $198 million, Adjusted EBITDA of $577 million, and Adjusted net income of $300 million in the second quarter.Reported an average …

MagnaChip Semiconductor Corp (MX) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis of MagnaChip Semiconductor Corp (MX), highlighting its current valuation score, P/E ratio, and ranking within the Semiconductors & Semiconductor Equipment industry. It notes that key valuation data like P/B, P/S, and P/CF have not yet been disclosed by …

MagnaChip Semiconductor Corp (MX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of MagnaChip Semiconductor Corp (MX), focusing on its support and resistance levels, various technical indicators, and moving averages. The stock's current price momentum score is 5.19, trading between resistance at $4.12 and support at $2.45. The analysis indicates …